Table 1.
Characteristics of 145 HIV-2-infected patients.
| Characteristic | Value |
|---|---|
| Men, n (%) | 79 (54) |
| Age, median years (IQR) | 45 (38–51) |
| Pre-ART CD4+ T-cell count, median cells/µl (IQR) | 171 (94–285) |
| Current CD4+ T-cell count, median cells/µl (IQR) | 360 (215–528) |
| Time since HIV-2 diagnosis, median years (IQR) | 5(2–7) |
| Time since first antiretroviral therapy, median years (IQR) | 4(2–7) |
| Patients in first-line regimen, n (%) | 48 (33) |
| First ART regimen, n (%) | |
| PI-based | 112 (77) |
| Lopinavir +/− ritonavir | 67 |
| Indinavir +/− ritonavir | 37 (17 with ritonavir) |
| Nelfinavir | 8 |
| Dual or triple NRTI | 13 (9) |
| NNRTI-based | 20 (14) |
| Patients still receiving their first-line ART regimen, n (%) | 48 (33) |
| Current ART regimen, n (%) | |
| PI-based | 137 (94) |
| Lopinavir/ritonavir | 131 |
| Darunavir/ritonavir | 2 |
| Saquinavir | 2 |
| Indinavir | 2 |
| Triple NRTI | 8 (6) |
| NNRTI-based | 0 (0) |
ART, antiretroviral therapy; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.